83 related articles for article (PubMed ID: 22388160)
1. Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al.
Seeman P
J Clin Psychopharmacol; 2012 Apr; 32(2):291-2; author reply 292-293. PubMed ID: 22388160
[No Abstract] [Full Text] [Related]
2. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Kinon BJ; Zhang L; Millen BA; Osuntokun OO; Williams JE; Kollack-Walker S; Jackson K; Kryzhanovskaya L; Jarkova N;
J Clin Psychopharmacol; 2011 Jun; 31(3):349-55. PubMed ID: 21508856
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.
Liu W; Downing AC; Munsie LM; Chen P; Reed MR; Ruble CL; Landschulz KT; Kinon BJ; Nisenbaum LK
Pharmacogenomics J; 2012 Jun; 12(3):246-54. PubMed ID: 21173788
[TBL] [Abstract][Full Text] [Related]
4. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Stauffer VL; Millen BA; Andersen S; Kinon BJ; Lagrandeur L; Lindenmayer JP; Gomez JC
Schizophr Res; 2013 Nov; 150(2-3):434-41. PubMed ID: 24035403
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia.
Kinon BJ; Gómez JC
Neuropharmacology; 2013 Mar; 66():82-6. PubMed ID: 22722029
[TBL] [Abstract][Full Text] [Related]
6. [The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].
Mosolov SN; Smulevich AB; Neznanov NG; Tochilov VA; Andreev BV; Avedisova AS; Bardenshteĭn LM; Gurovich IIa; Reznik AM; Zharkova NB; Martenyi F
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(7):16-23. PubMed ID: 20639852
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive benzodiazepines in acute schizophrenia.
Cohen S; Khan A
Neuropsychobiology; 1987; 18(1):9-12. PubMed ID: 2895435
[TBL] [Abstract][Full Text] [Related]
10. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Patil ST; Zhang L; Martenyi F; Lowe SL; Jackson KA; Andreev BV; Avedisova AS; Bardenstein LM; Gurovich IY; Morozova MA; Mosolov SN; Neznanov NG; Reznik AM; Smulevich AB; Tochilov VA; Johnson BG; Monn JA; Schoepp DD
Nat Med; 2007 Sep; 13(9):1102-7. PubMed ID: 17767166
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
Citrome L
Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
[TBL] [Abstract][Full Text] [Related]
12. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
[TBL] [Abstract][Full Text] [Related]
13. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
Poyurovsky M; Faragian S; Fuchs C; Pashinian A
Isr J Psychiatry Relat Sci; 2009; 46(3):213-20. PubMed ID: 20039523
[TBL] [Abstract][Full Text] [Related]
14. A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
Ermilov M; Gelfin E; Levin R; Lichtenberg P; Hashimoto K; Javitt DC; Heresco-Levy U
Schizophr Res; 2013 Nov; 150(2-3):604-5. PubMed ID: 24094884
[No Abstract] [Full Text] [Related]
15. Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia.
Mössner R; Schuhmacher A; Schulze-Rauschenbach S; Kühn KU; Rujescu D; Rietschel M; Zobel A; Franke P; Wölwer W; Gaebel W; Häfner H; Wagner M; Maier W
Eur Neuropsychopharmacol; 2008 Oct; 18(10):768-72. PubMed ID: 18614340
[TBL] [Abstract][Full Text] [Related]
16. Benzodiazepines in schizophrenia: a need for reassessment.
Nestoros JN
Int Pharmacopsychiatry; 1980; 15(3):171-9. PubMed ID: 6113219
[TBL] [Abstract][Full Text] [Related]
17. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
Kinon BJ; Volavka J; Stauffer V; Edwards SE; Liu-Seifert H; Chen L; Adams DH; Lindenmayer JP; McEvoy JP; Buckley PF; Lieberman JA; Meltzer HY; Wilson DR; Citrome L
J Clin Psychopharmacol; 2008 Aug; 28(4):392-400. PubMed ID: 18626265
[TBL] [Abstract][Full Text] [Related]
18. Adolescent with treatment-refractory schizophrenia and clozapine-induced cardiomyopathy managed with high-dose olanzapine.
Bobb VT; Jarskog LF; Coffey BJ
J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):539-43. PubMed ID: 21186975
[No Abstract] [Full Text] [Related]
19. Selecting antipsychotics in schizophrenia: lessons from CATIE.
Haddad P; Dursun SM
J Psychopharmacol; 2006 May; 20(3):332-4. PubMed ID: 16574710
[No Abstract] [Full Text] [Related]
20. Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms.
Xiao S; Xue H; Li G; Yuan C; Li X; Chen C; Wu HZ; Mitchell P; Zhang M
Aust N Z J Psychiatry; 2012 Feb; 46(2):153-60. PubMed ID: 22311531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
